Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.
Teigler JE, Zelinskyy G, Eller MA, Bolton DL, Marovich M, Gordon AD, Alrubayyi A, Alter G, Robb ML, Martin JN, Deeks SG, Michael NL, Dittmer U, Streeck H. Teigler JE, et al. J Virol. 2017 Nov 14;91(23):e01263-17. doi: 10.1128/JVI.01263-17. Print 2017 Dec 1. J Virol. 2017. PMID: 28904197 Free PMC article.
Blocking the function of inhibitory receptors such as PD-1, CTLA-4, 2B4, Tim-3, and LAG-3 has shown promise for augmenting CD8 T cell activity and boosting pathogen-specific immunity. ...We therefore determined and compared inhibitory receptor expression patterns of 2B4, C …
Blocking the function of inhibitory receptors such as PD-1, CTLA-4, 2B4, Tim-3, and LAG-3 has shown promise for augmenting CD8 T cell …